Medicine
Showing 701-720 of 2,424 Results
-
Jason Gotlib
Professor of Medicine (Hematology)
Current Research and Scholarly InterestsMy research interests include phase I/II clinical trial evaluation of novel therapies for the following diseases:
--Myelodysplastic syndromes (MDS)
--Chronic myelogenous leukemia (CML)
--Acute myelogenous leukemia (AML)
--Myeloproliferative disorders (MPDs) including:
Hypereosinophilic syndrome
Systemic mastocytosis
BCR-ABL-negative MPDs -
Thirumagal Gowrikanthan
Affiliate, Medicine - Med/Family and Community Medicine
BioThirumagal Gowrikanthan is an undergraduate student at McMaster University pursuing a degree in Life Sciences (HB.Sc.) along with a Concurrent Certificate in Science Communication. In addition to her research at McMaster, which focuses on knowledge translation and cardiology, she is a Research Scholar with the Stanford University School of Medicine, where she conducts research to advance the health of Asian populations through data science. Her broader interests include enhancing patient care by translating research into practice and bridging the gap between research and clinical application to ensure healthcare is accessible to all.
-
Philip Grant
Clinical Associate Professor, Medicine - Infectious Diseases
BioMy research focuses on antiretroviral therapy and complications of HIV including immune reconstitution inflammatory disease, osteoporosis, and cardiovascular disease.
-
Harry B Greenberg
Joseph D. Grant Professor in the School of Medicine, Emeritus
Current Research and Scholarly InterestsMolecular mechanisms of pathogenesis; determinants of protective immunity; host range and tissue tropism in liver and GI tract pathogenic viruses and studies of vaccines in people.
-
Peter Greenberg
Professor of Medicine (Hematology), Emeritus
Current Research and Scholarly InterestsDr Greenberg's clinical research involves design and coordination of clinical trials using experimental drugs with biologic focus for both lower and higher risk MDS patients not responding to standard therapies. These studies are particularly based on his prior laboratory investigations of gene expression and hematopoietic regulation in MDS patients. He is Coordinator of the International Working Group for Prognosis in MDS (IWG-PM) which generated the revised MDS classification system (the IPSS-R) and the mutation-based prognostic risk system, the IPSS-Molecular (IPSS-M). This project uses such findings to more specifically characterize and treat MDS patients. He is Chair of the NCCN Practice Guidelines Panel for MDS.
